Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification

Oncogene

Volumn 30, Issue 39, 2011, Pages 4097-4106

  Tanizaki, J ^a   Okamoto, I ^a   Fumita, S ^a   Okamoto, W ^a   Nishio, K ^a   Nakagawa, K ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

apoptosis; BIM; breast cancer; HER2 amplification; PIK3 CA mutation; survivin

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; BETA ACTIN; BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; SELUMETINIB; SMALL INTERFERING RNA; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85027953975     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.111     Document Type: Article

References (37)

1. Altieri DC. (2003). Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54. (Pubitemid 37328886)
2. Ambrosini G, Adida C, Altieri DC. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921. (Pubitemid 27353455)
3. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402. (Pubitemid 47539306)
4. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H et al. (2009). Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 106: 22299-22304.
5. Burris III HA, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N et al. (2009). A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15: 6702-6708.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403. (Pubitemid 40193310)
7. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ et al. (2007). BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 4: 1669-1679; discussion 1680.
8. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. (2008). Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118: 3651-3659.
9. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. (2007). Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 4: 1681-1689; discussion 1690.
10. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC et al. (2008). Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552.
11. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W et al. (2008). Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phospha-tidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221-9230.
12. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743. (Pubitemid 46021510)
13. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S et al. (2008). Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999-3005.
14. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X et al. (2007). Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adeno-carcinomas. PLoS Med 4: e294.
15. Gymnopoulos M, Elsliger MA, Vogt PK. (2007). Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104: 5569-5574. (Pubitemid 47175721)
16. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K et al. (2009). in vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649-4664.
17. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV et al. (2005). Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000. (Pubitemid 41713369)
18. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. (2001). Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 93: 1541-1552. (Pubitemid 32998483)
19. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. (2010). Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21: 255-262.
20. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-trea-ted breast cancer cells. Cancer Res 66: 1630-1639. (Pubitemid 43259947)
21. LoRusso PM, Jones SF, Koch KM, Arya N, Fleming RA, Loftiss J et al. (2008). Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26: 3051-3056.
22. McKenzie JA, Liu T, Goodson AG, Grossman D. (2010). Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 inte. Cancer Res 70: 7927-7937.
23. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al. (2000). A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809. (Pubitemid 30395796)
24. Peirce SK, Findley HW, Prince C, Dasgupta A, Cooper T, Durden DL. (2010). The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol (e-pub ahead of print 24 October 2010; DOI:10.1007/s00280-1010-1486-7).
25. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559. (Pubitemid 40490050)
26. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554. (Pubitemid 38541907)
27. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
28. Slamon DJ. (1990). Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest 8: 253.
29. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
30. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712. (Pubitemid 19147683)
31. Speliotes EK, Uren A, Vaux D, Horvitz HR. (2000). The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone. Mol Cell 6: 211-223.
32. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
33. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. (2000). Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134. (Pubitemid 30064984)
34. Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y et al. (2009). Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101: 1676-1682.
35. Uren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL et al. (2000). Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 10: 1319-1328.
36. Zhang H, Liu G, Dziubinski M, Yang Z, Ethier SP, Wu G. (2008). Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat 112: 217-227.
37. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. (2005). The oncogenic properties of mutant p110alpha and p110beta phospha-tidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102: 18443-18448. (Pubitemid 43011245)